Clinical Trial News

Clinical Trial News

Abstracts by Tom Swartz

[Editor's Note: Because the Clinical Trial News column is so highly accessed, we have reduced the need for you to "search" back issues of ESUN to locate clinical study information. We have created three separate webpages where all of the clinical trial information that we have published in ESUN to date has been collected. You can read about these changes in the editorial, Changes Made, in the October 2006 issue of ESUN. With the addition of the 9 clinical trials described in this issue of ESUN, we now have over 180 clinical trials listed on our website.]

Currently Accepting Eligible Patients (not previously published in ESUN)

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

This Phase I trial is currently recruiting patients. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and sunitinib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with sunitinib may kill more tumor cells. The purpose of this trial is to study the side effects and best dose of bevacizumab and sunitinib in treating patients with solid tumors. This is a multicenter, dose-escalation study. Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and oral sunitinib malate (SU11248) once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of bevacizumab and SU11248 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 10 patients are treated at the MTD. After completion of study therapy, patients are followed for 30 days. A total of 24 patients will be accrued for this study. Patients 18 years of age and older are eligible. This trial is taking place at the Case Comprehensive Cancer Center, Cleveland, Ohio.

Registry Information

Official Title: A Phase I Study of Bevacizumab in Combination with SU11248

Trial Start Date: 2006-06-01

Registered in ClinicalTrials.gov: NCT00357318

Date Submitted to PDQ: 2006-05-31

Information Last Updated: 2007-02-20

NCI Grant/Contract Number: CA43703

Imatinib Mesylate, Bevacizumab, and Cyclophosphamide in Treating Patients With Refractory Metastatic Solid Tumors

This Phase I trial is currently recruiting patients. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab and cyclophosphamide may also stop the growth of tumor cells by blocking blood flow to the tumor. Imatinib mesylate and bevacizumab may help cyclophosphamide work better by making tumor cells more sensitive to the drug. Giving cyclophosphamide once a day together with imatinib mesylate and bevacizumab may kill more tumor cells. The purpose of this trial is to study the side effects and best dose of imatinib mesylate when given together with bevacizumab and cyclophosphamide in treating patients with refractory metastatic solid tumors. This is a nonrandomized, open-label, pilot, dose-escalation study of imatinib mesylate. Patients receive oral cyclophosphamide and oral imatinib mesylate once daily on days 1-28 and bevacizumab IV on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD. A total of 21 patients will be accrued for this study. Patients 18 years of age and older are eligible. This trial is taking place at the University of California, San Francisco,

Registry Information

Official Title: A Phase I Trial of Imatinib Mesylate, Bevacizumab, & Metronomic Cyclophosphamide as Antiangiogenic Therapy in Refractory Metastatic Solid Tumors

Trial Start Date: 2006-08-15

Registered in ClinicalTrials.gov: NCT00390156

Date Submitted to PDQ: 2006-09-11

Information Last Updated: 2007-05-23

NCI Grant/Contract Number: CA82103

Not Yet Recruiting Patients (not previously published in ESUN)

There are no entries in this category for the April 2007 Issue of ESUN.

Comments and Suggestions

We would appreciate receiving any comments or suggestions regarding the contents of the Clinical Trials News column. Please send us pointers to clinical trials that should be included in this column. Click here to send us a note.